CERRITO MARIA GRAZIA

Role
Administrative-Technical Staff  
Office phone
Room:
  • U08, Floor: 4, Room: L4.6B

Publications

  • Ilari, A., Cogliati, V., Sherif, N., Grassilli, E., Ramazzotti, D., Cordani, N., et al. (2024). Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer. BIOMEDICINES, 12(2) [10.3390/biomedicines12020272]. Detail

  • Grassilli, E., Cerrito, M. (2023). "Ironing out" fasting-induced persister cancer cells to render chemotherapy effective: is this the solution?. EBIOMEDICINE, 90(April 2023) [10.1016/j.ebiom.2023.104542]. Detail

  • Cordani, N., Lisini, D., Coccè, V., Paglia, G., Meanti, R., Cerrito, M., et al. (2023). Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC). INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(6), 1-16 [10.3390/ijms24065864]. Detail

  • Cordani, N., Mologni, L., Piazza, R., Tettamanti, P., Cogliati, V., Mauri, M., et al. (2023). TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(22) [10.3390/ijms242216294]. Detail

  • Meazza Prina, M., Gotuzzo, I., Cazzaniga, M., De Bernardi, E., Cafaro, P., Capici, S., et al. (2023). Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study. Intervento presentato a: SABCS - San Antonio Breast Cancer Symposium - DEC 06-10, 2022, San Antonio, Texas, USA [10.1158/1538-7445.SABCS22-P6-01-42]. Detail